Potentially first-in-class oral TNIK inhibitor advances into late-stage development after milestones marked by vital peer-reviewed papers: the discovery-to-clinic journey in Nature Biotechnology, and ...
Background Janus kinase inhibitors (JAKis) are emerging therapies for SLE, but concerns regarding thromboembolic risk persist ...
Researchers at the University of Bayreuth and Forschungszentrum Jülich have demonstrated that specific light-sensitive ...
Treatment with a once-daily FGFR1-3 tyrosine kinase inhibitor led to significant increases in growth among children with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results